Amro Albanna ( 00:04 ): Welcome everybody. Just as always, I'm gonna wait a few seconds here to see to just let to wait on people joining. I am looking at the attendees list, and we're just gonna wait a few more seconds

Amro Albanna (00:04):

Welcome everybody. Just as always, I'm gonna wait a few seconds here

to see to just let to wait on people joining. I am looking at the attendees list, and we're just gonna wait a few more seconds as we see

people coming in to make sure that we don't miss out on recording the full session. [00:00:30] All right. Just more attendees are joining,

and maybe with that we can, we can get started. Welcome everybody. Saundra, how are you?

Saundra Pelletier (00:42):

I'm great. Thank you for having me. I'm actually very happy to be here

Amro Albanna (00:46):

Thank you. Thanks, thanks, Saundra. So, look it really is important

for us, as we discussed, as far as, you know, these weekly updates to make sure that our stakeholders collectively, they do [00:01:00]

understand where we are what we're trying to address, and most importantly, why we're doing this. And while you and I speak, I don't know,

twice a day, three, four times, sometimes a day obviously the, you know, you know, especially people on the outside don't see those dynamics,

and it's really important for us to be, you know, to, to really communicate what's going on so they understand that this is not just a

you know, a a a process of documentation and [00:01:30] m and a. This is a lot more of a partnership that we're trying to get done, and

we're trying to get it done for a good reason. So, with that said, I know everybody knows Saundra, but maybe just for, you know for, for

whoever who doesn't, maybe you can do a quick intro and we'll take it from there.

Saundra Pelletier (01:45):

Yeah. Great. Thank you, Amro. So, I'm Saundra Pelletier. I am the CEO

of Evofem Biosciences. And our alignment with aditXt really is critical because aditXt has identified the need to partner to [00:02:00]

really help rise women's health. And women are half the population, and our company has two FDA approved products that are innovative

and absolutely unique. And the first is Phexxi. As you see, I'm wearing my Phexxi shirt. It is the first and the only FDA approved birth

control that women use on demand only when they need it, never when they don't. I say that statement specifically because right now, when

women [00:02:30] are given hormonal birth control, synthetic birth control, they have to take a product every single day of every week

of every month for years. And women don't have sex every day. So if women are having side effects, which many women do, having something

they use only when they need it, is game changing for the quality of life of women.

Saundra Pelletier (02:50):

So that's Phexxi. Also, with the help of aditXt, we were able to acquire

our second FDA approved product called, Solosec. [00:03:00] Solosec treats bacterial vaginosis and trichomoniasis, pervasive infections.

It is the same call point. Our reps call on OBGYNs to talk about Phexxi and Solosec, but here's what makes Solosec better. Before Solosec

or without Solosec, women were asked to take a product twice a day for seven to 14 days. Solosec is a silver bullet. It's one and done.

You go in and you have discharge and odor and vaginal pain, [00:03:30] and you're given one sachet. You mix it in applesauce, pudding

and or yogurt, and you take it one time, you are done. The dosing regimen is superior. So we have two very unique, wonderful products,

and the partnership with aditXt has allowed us to keep offering solutions for women and which offers solutions for investors. So that

was a long answer, Amro, I'm sorry. But yeah, great.

Amro Albanna (03:57):

I mean, you know, I'm a big fan of, I'm a big fan. I'm [00:04:00] a

big fan. Saundra, you can articulate women's health and better than anyone. So look, and it is mutual. It really, this

is, this has been a two-way street, two-way partnership. And look, while we are a young company, aditXt, right? We are a young company

and we all understand, you know, the nature of, of being an early stage, that this is something where we believe in as far as women's

health, starting with Adimune, we have the autoimmune program, which [00:04:30] we'll talk about at the end of the program. And as far

as our plan for an update, we have Pearsanta with early diagnostics, starting with cancer and endometriosis speaking women's health. And

we are working on establishing women's health through the acquisition and the transaction we currently have.

Amro Albanna (04:46):

And with that said, look, we, we continue myself Saundra, our team,

we continue to push forward to, you know, targeting, to close the acquisition by September. And [00:05:00] that is still our commitment.

That has not changed, knowing that we do have certain conditions we have to address, right? We do. And that's why it's, it's, it has taken

a long time and we must address these conditions, but the fact that we're still here and we're still pushing forward, obviously we both

believe in, in, in the partnership and what it can do beyond September and beyond the acquisition. So, before I go further, please just

remember that we really encourage [00:05:30] questions Q and A. You have at the bottom of the screen a way to ask questions. And whether

it's for me or Saundra, please go ahead and ask questions as we go. You don't have to wait until the end of the session.

Amro Albanna (05:41):

You can ask as we, as we do this live. So that's, that's a little bit

of the background and what we've been working on. So, Saundra, what was your, you know, you know, women's health and we chatted a little

bit before as far as the direction, and you wanted to make sure that Evofem is not a single product [00:06:00] company for obvious reasons.

Number one you know, there are all types of needs when it comes to women's health. It's not just you know, it's not just what Evofem provides.

You mentioned Solosec, and we talked about monitoring, prevention, and treatment. So, with Phexxi, it addresses the, at least it really

is a product that fits in prevention with Solosec, it fits in treatment. And we discussed endometriosis, and I see Chris on the line here

from Pearsanta. [00:06:30] And not to put you on the spot, why don't you talk a little bit about endometriosis and if it becomes a service

as part of Evofem, what would that do for Evofem as a as you know, a company providing a monitoring and a diagnostic service and the market

Saundra Pelletier (06:48):

Yeah, so the one thing that I want everybody, all the partners, constituents,

investors to hear is that even though Evofem is also small, we really have [00:07:00] been categorized by doctors, by nurses, by nurse

practitioners and midwives as the company that does the tough things, right? Bringing some of these products to market or resurrecting

a product like Solosec. So the idea that we are gonna have something for endometriosis, you have to remember that infertility is pervasive.

Young women are paralyzed with fear about IVF, you know, not just about the financial aspect of it, [00:07:30] but the emotional aspect

of it. And endometriosis is one of the main causes of infertility. So if we have a way for detection, it is going to be so valuable, one

for the credibility of our offerings, two for the mission that all of our organizations wanna deliver on. And the idea that we want to

be innovative, right?

Saundra Pelletier (07:52):

You don't wanna wait until it's too late, right? You wanna be able

to, you solve problems for women when detection is early. So endometriosis [00:08:00] is something that is, when you do market research

with women, what you see is the pain that they have, the fear that they have, the lack of information and education and offices really

want help and solutions. So, so one endometriosis is huge. The other great thing though is that this exact same technology will be able

to be developed over time for ovarian cancer. Ovarian cancer is the silent killer of women, [00:08:30] period. And everyone that I talk

to, the idea that we are continuing to innovate, and that to your point, right, we will have something for all of these stages of clinical

solutions for women. The partnership with Pearsanta is just gonna make our offering more robust, but not just because we want another

Saundra Pelletier (08:55):

The one thing that I think Amro you and I agree upon is that [00:09:00]

just having anything is not enough. We want to be differentiated as a company that has value, that continues to have credibility by solutions

that are better, period. So that's what, that's what this Pearsanta technology has. So, and we've done a lot of research, by the way,

I've been in women's health my whole life. I'm really 250 years old. I just live in California, so I get a lot of facials, ,

but I'm telling you this, that it is real. We're very exciting. The other point is, is we already have the footprint, [00:09:30] right?

That's the one thing that we love about you and Chris at Pearsanta, is that we built the footprint, which by the way, is not inexpensive,

okay? And we got a lot of judgment from investors. Why don't you outsource?

Saundra Pelletier (09:43):

Why don't you use the contract sales force? Well, I can tell you that

you need to inspect what you expect. Contract sales forces are the B team. They're not the A team. We needed the A team to deliver, to

really deliver value for women [00:10:00] and investors. That's why we invested in it. I will never regret that decision. But yes, more

products is better. And the final thing I wanna say is when you have a sales team that has launched Phexxi almost three years ago, then

we had Solosec, right? This year, by the time we get ready for endometriosis, the Salesforce is gonna be ready for new conversations.

So we're very excited about this because it, it makes so much sense. So I'm telling,

Amro Albanna (10:28):

Yeah, and that's, and that is an important point. 'cause [00:10:30]

Look, I mean, as, as you know, I mean, we're, you know, capital is key, obviously for all of us, but reality is, we always talk, as far

as, you know, with aditXt, it really isn't about capital. I mean, we all figure out how to make sure we try to get the fuel, and, and

our team knows it's, it's a challenge. And I'm sure your team knows it is a challenge, but ultimately the key to building a business is

having these synergies, like the one you just talked about with, with Pearsanta. And [00:11:00] it goes both ways for Pearsanta. You're

a, you, you know, Evofem is a, is a great partner, great channel, you understand women's health, you have the existing relationships,

you have the foundation, you have the platform. So with that said, look, our, you know, a majority of our work right now in the next probably

90 to 120 days, is to figure out how we can get this transaction to a close.